Biotech Week articles from October 2002

Biotech Week archives from October 2002

New possibilities for deadly childhood brain cancer.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- The most common brain cancer in children may have an Achilles' heel - the signal from a protein called Hedgehog - according to a report in the journal Science. Scientists from Johns Hopkins Medical...

Artificial liver trials show progress, as transplant candidates wait.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Four years after the first American clinical trial of an experimental artificial liver system began at the University of Michigan Health System (UMHS), its leader says he is encouraged by the results...

Faslodex data published in Journal of Clinical Oncology.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Results from two clinical trials evaluating Faslodex (fulvestrant) Injection in treating advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy was...

Mass spectrometer weighs in as proteomics breakthrough.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- A faster, more thorough mass spectrometry method for identifying proteins may significantly advance the technology infrastructure required to comprehend the role proteins play in cellular function and...

Xyotax to be tested in recurrent, chemotherapy-resistant cancer.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Cell Therapeutics, Inc., (CTI) (CTIC) announced that the Gynecologic Oncology Group (GOG), a cooperative of many of the most prominent physicians and institutions in the United States, has activated a...

New antidepressant awaited, but little proof it's much better.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- U.S. psychiatrists can now prescribe an eagerly awaited new antidepressant called Lexapro. It's being promoted as more potent and possibly safer than older competitors - but there's little evidence that...

Phase II trial for VitrenASE initiated.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Immusol, The Inverse Genomics Co., announced that it has initiated a phase II clinical trial for its lead product, VitrenASE, for proliferative vitreoretinopathy (PVR), a serious eye disease...

FDA approves blood pressure treatment for additional indication.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- The U.S. Food & Drug Administration (FDA) approved a leading high blood pressure medicine Diovan (valsartan) to treat heart failure in patients who are intolerant of angiotensin-converting-enzyme (ACE)...

Multiantigen vaccine effective against malaria in rhesus macaques.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Rhesus macaques were protected against a lethal Plasmodium knowlesi infection by immunization with a vaccine composed of cytokines and DNA plasmids...

Judge rules OxyContin lawsuit can be class action.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- A lawsuit that accuses the makers of OxyContin of irresponsibly marketing the powerful painkiller to Ohioans has been certified as a class action. "The abuse, intentional or accidental, of...

Court of Appeals victory for generic version of Depakote.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Apotex Corp. announced that the Court of Appeals for the Federal Circuit reversed a summary judgment that the U.S. District Court for the Northern District of Illinois granted last year in Abbott's suit...

Company unveils new management lineup.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- BioVisioN AG has appointed Wolfgang Trefzger as CFO and Dr. Rudolf Reiter, hitherto director of project management, as chief operating officer. Dr. Michael Schrader, former COO, has left the...

Cash expenditures cut by 60%.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- CEL-SCI Corporation (CVM) reports financial results for the 3 months ending June 30, 2002. The revenue for the quarter from April 1, 2002, until June 30, 2002, was $107,511 compared with $213,490 in...

$26M GMP contract bioprocessing expansion announced.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Cambrex Corporation (CBM) announced that its board of directors approved a $26 million expansion of its GMP contract bioprocessing capacity. The investment consists of two projects to support...

Collaboration expanded for target characterization, drug discovery.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Cambridge Antibody Technology (CATG; CAT) and Xerion Pharmaceuticals AG announced the expansion of their existing business relationship into a research collaboration for target characterization and drug...

Vaccinia hyperimmune globulin contract awarded.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Cangene announces that it has been awarded a contract by the United States Centers for Disease Control and Prevention to develop and supply a vaccinia immune globulin (VIg) for use in treating and...

FDA approval granted for meperidine hydrochloride.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Caraco Pharmaceutical Laboratories, Ltd., (CARA) has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market meperidine hydrochloride, a generic form of Sanofi-...

Second quarter net losses: $0.09 per share.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Carrington Laboratories, Inc., (CARN) will file its Form 10-Q with the Securities Exchange Commission, including CEO and CFO certifications, reporting revenues for the second quarter ended June 30,...

Luminex Corp. announces license and supply agreement.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Luminex Corp. (LMNX) announced the execution of a license and supply agreement with Celera Diagnostics, a joint venture between the Applied Biosystems Group (ABI), and the Celera Genomics Group (CRA) of...

Broad patent covers oncolytic virus therapies.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Cell Genesys, Inc., (CEGE) announced that it has been issued a broad patent (U.S. Patent No. 6,432,700) that includes specific composition of matter claims pertaining to the company's proprietary...

New drug discovery facility opens.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Cellular Genomics, Inc., (CGI), announced the opening of its facility for small molecule drug discovery at the company's headquarters in Branford Connecticut. The 9000 square foot facility will...

510 K filed with FDA for DNA-based group B strep test.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Cepheid (CPHD) announced that its joint venture partner, Infectio Diagnostic (IDI), has issued a press release regarding its filing of a 510 K with the FDA for a group B streptococcus (GBS) test. ...

Patent granted covering ultrasonic lysis in test cartridges.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Cepheid (CPHD) announced the issuance of U.S. Patent No. 6,431,476 covering apparatus and methods for lysing cells and microorganisms in cartridges using ultrasonic energy. This technology is a key...

CEO, CFO voluntarily file SEC certification.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Cerner Corporation (CERN) today filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) transmitting sworn statements by Neal Patterson, its CEO, and Marc Naughton, its chief financial...

Pharmaceutical executive added to board of directors.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Ciphergen Biosystems, Inc., (CIPH) announced that Wendell Wierenga, CEO of Syrrx, Inc., has joined Ciphergen's board of directors. Since September 2000, Wierenga has served as the CEO of Syrrx, a...

Phase III trial of product for prevention of graft failure begins.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Corgentech, Inc., a privately held biotechnology company, announced that enrollment has begun in a pivotal phase III clinical trial evaluating its lead product, E2F Decoy, as a potential treatment for...

Record second quarter results reported.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Covalent Group, Inc., (CVGR) announced record financial results for the second quarter ended June 30, 2002. Net revenue increased 30% to $6.2 million as compared with $4.8 million for the same...

PER.C6 licensing agreement signed with GenVec.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Dutch antibody and vaccine company Crucell N.V. (CRXL) announced that it has signed a licensing agreement with GenVec, a biopharmaceutical company developing gene-based medicines, to use the PER.C6 cell...

Medical device company details responses to FDA.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- CryoLife, Inc., (CRY), a leader in the development and commercialization of living human tissue implantable devices, and a manufacturer and distributor of stentless heart valves and surgical adhesives,...

Company announces stock repurchase program.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Curon Medical, Inc., (CURN) announced that its board of directors has approved a stock repurchase program pursuant to which up to 1,000,000 shares of its outstanding common stock may be repurchased from...

FDA approves Glucowatch for children.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- The U.S. Food and Drug Administration (FDA) has approved a wrist watch-like glucose monitoring device for use by children and adolescents with diabetes. The device, which was approved for adult use in...

Date for compliance with NASDAQ minimum bid price extended.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- CytRx Corporation (CYTR) announced that the Nasdaq Stock Market has extended the date by which the company must comply with the $1.00 minimum closing bid price requirement from August 13, 2002, until...

Key ruling issued on European vaccine microsphere patent.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- DOR BioPharma, Inc., announced that the company has been notified of a decision of the Technical Board of Appeal of the European Patent Office in the defense of European patent EP0 266 119 against an...

Second quarter 2002 net loss: $0.32 per share.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- DOV Pharmaceutical, Inc., (DOVP) announced results for the second quarter ending June 30, 2002. For the second quarter of 2002, the company reported a net loss of $3.8 million, or $0.32 per share,...

Cancer pathway targeted by a collaboration.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- The Northern Institute for Cancer Research at the University of Newcastle and Cancer Research Ventures, Ltd., are pleased to announce that they have entered into a collaborative agreement for the...

Company announces $1.5M in proceeds from Acqua draw.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Dimethaid Research, Inc., (DMX) announced it has received gross proceeds of CDN$1.5 million against the issuance of 508,475 shares of common stock pursuant to its private placement agreement with Acqua...

EluSys gets grant for anthrax drug.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- A biotech startup company has won a $2.8 million U.S. government grant to help refine technology to destroy toxins that anthrax bacteria release in the bloodstream. The grant is the government's...

Delisting notice issued from Nasdaq.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Enchira Biotechnology Corporation (ENBC) announced that it received a Nasdaq Staff Determination on August 14, 2002, indicating that the company fails to meet the minimum bid price requirement for...

Surgical implant and device producer reports record 2Q sales.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Encore Medical Corporation (ENMC) announced sales of $25.6 million for the second quarter ended June 29, 2002, an increase of 205% over the $8.4 million in the second quarter of 2001. For the first...

Mobile business of U.S. Medical Development acquired.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Endocare, Inc., (ENDO), a developer of innovative diagnostic and treatment tools for cancer and other diseases, announced that it has executed a definitive agreement to acquire the mobile prostate...

Angiogenesis R&D company reports second quarter 2002 net losses.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- EntreMed, Inc., (ENMD), a biopharmaceutical leader in angiogenesis research and product development, reported results for the 3-month quarter ending June 30, 2002. Revenues for the second quarter...

New patent filed; second quarter performance reported.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Entropin, Inc., (ETOP) (ETOPW), a specialty pharmaceutical company developing new topical therapeutics for painful soft tissue injuries and diseases, reported financial results for the 3 and 6 months...

Additional patent issued for PADRE technology.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Epimmune, Inc., (EPMN), a biotechnology company focused on the development of pharmaceutical products using multiple, specific epitopes to activate the body's immune system, announced that the U.S....

New chief technical officer hired by developer of nucleic acid technologies.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- EraGen Biosciences, Inc., a leading developer of nucleic acid and proteomic technologies, introduces Gary Madsen, PhD as its new chief technical officer. As a company prepared to enter the...

Genomics drug discovery company reports strong performance for second quarter, first half 2002.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- GPC Biotech AG (GPC), a leading genomics- and proteomics-driven drug discovery and development company, reported its financial results and course of business for the second quarter and 6 months ended...

6.5$M in equity, debt funding secured by genetics company.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Galileo Genomics, Inc., a Montreal-based population genetics company, announced it has secured an additional $6.5 million in equity and debt funding. Bio Fund of Finland, the equity investor,...

Molecular HIV/HCV screen fast, accurate.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United States say that a nucleic acid test can quickly and accurately find HIV and hepatitis C virus (HCV) in donated blood. Janet Vargo...

Second quarter 2002 revenues increase 12.3% says molecular diagnostics firm.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Gen-Probe, Inc., an established leader in molecular diagnostics based on its patented nucleic acid testing (NAT) technologies, reported its financial results for the second quarter and 6 months ended...

Net loss for 2Q reported at $0.01 per share.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- GenSci Regeneration Sciences, Inc., The Orthobiologics Technology Company, announced that cash, restricted cash, and short-term investments at June 30, 2002, increased 86% to $5 million compared with...

Second quarter 2002 net loss reported by developer of medicines from genomics, natural products.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Genaera Corporation (GENR) announced its financial results for the 3 and 6 months ended June 30, 2002. The net loss applicable to common shareholders for the 3 months ended June 30, 2002, was...

Company announces naked shorting evidence, steps to control trading abuses.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- GeneMax Corp. (GMXX; GX1) announced that it is taking increased measures to ensure that trading in the shares of the company occurs in a fair and appropriate manner. Shareholders have complained to...

Company granted controlled drugs, substances license.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Generex Biotechnology Corporation (GNBT), a leader in the area of buccal drug delivery, announced that it has been granted a Controlled Drugs & Substances License by Health Canada. The license...

Positive results of long-term safety, toxicology study of Oralin reported.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Generex Biotechnology Corporation (GNBT), a leader in the area of buccal drug delivery, announced continued positive results from its long-term (two years) safety and toxicology study of Oralin, the...

ICN Pharmaceuticals will not complete acquisition.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Genetronics Biomedical Corporation, San Diego, (GEB) announced that ICN Pharmaceuticals (ICN) has decided not to proceed with its planned acquisition of Genetronics' BTX Division. The decision not...

Drug therapy attempts to avoid dialysis.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- GenoMed, Inc., (GMED) a St. Louis, Missouri-based medical genomics biotechnology company, announced a new drug treatment based on pilot data that avoids dialysis in the setting of acute kidney failure....

Genomics-based drug discovery company shows 2Q 2002 net loss: $0.36 per share.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Genome Therapeutics Corp. (GENE) released financial results for the second quarter ended June 29, 2002. In line with prior guidance, the company reported a net loss for the quarter of $8,317,000,...

KPMG named as independent auditor for genomic/proteomic instrumentation and services firm.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Genomic Solutions, Inc., (GNSL) announced that it has engaged KPMG LLP to serve as the company's independent public accountants for the fiscal year 2002. Genomic Solutions is filing a Form 8-K with...

Drug shows promise in treating severe, often-lethal complication of stem cell treatment.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- A study led by researchers at Dana-Farber Cancer Institute has shown that a drug extracted from porcine intestinal tissue reduced the risk of death in patients who experienced a severe and often-fatal...

Amprenavir prodrug can reduce pill burden.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - Researchers in the United Kingdom may have found a way to reduce HIV patients' pill burden during some antiretroviral drug regimens. C. Falcoz and...

Company signs agreement with VA for imaging systems.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Hologic, Inc., (HOLX), a leading provider of women's diagnostic imaging systems and state-of-the-art general digital radiography systems, announced it has been awarded a multiyear contract with the...

Patent issued covering novel CpG oligonucleotides.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HYBN.OB) announced the issuance of U.S. Patent No. 6,426,334 claiming a novel class of CpG oligonucleotides for the treatment of cancer. "The issuance of this patent makes Hybridon...

Second quarter net loss: $0.08 per share.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- ID Biomedical announced that it recorded an unaudited proforma net loss of $5.6 million or ($0.18) per share for the 3-month period ending June 30, 2002, as compared with a net loss of $2.3 million or...

Cholesterol 1,2,3 developer reports second quarter net loss: $0.06 per share.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- IMI International Medical Innovations, Inc., (TSX:IMI) announced results for its fiscal 2002 second quarter ended June 30, 2002. Key events during the quarter included the signing of a marketing...

Second quarter net loss reported at $0.39 per share.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- ISTA Pharmaceuticals, Inc., (ISTA), reported financial results for the quarter and 6 months ended June 30, 2002. ISTA reported a net loss of $6.6 million, or $0.39 per share, for the quarter ended...

Executive officers file certification with U.S. SEC.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Igen International, Inc., (Igen) reported that its chairman and CEO, Samuel J. Wohlstadter and its vice president and chief financial officer, George V. Migausky filed a certification with the U.S....

Clofarex web site launched.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Ilex Oncology, Inc., (ILXO) announced the launch of www.clofarex.com. Clofarex (clofarabine), a second-generation nucleoside analogue, is currently being studied as a potential treatment for...

Plan to certify annual report, financial statements announced by blood transfusion instrument maker.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Immucor, Inc., (BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced that its annual report on Form 10-K will be accompanied by the...

Increased licensing revenues improve operating results for antibody-based technology company.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Immunomedics, Inc., (IMMU) reported revenues of $4.3 million and a net loss of $1.8 million, or $0.04 per share, for the fourth quarter of its fiscal year ended June 30, 2002, excluding a one-time...

Third quarter yields net loss of $0.26 per share for company focusing on tissue damage.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Incara Pharmaceuticals Corporation (INCR) announced the financial results for its third quarter of fiscal 2002, the 3-month period ended June 30, 2002. The company also included recent progress...

Onco TCS clinical program expanded.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Inex Pharmaceuticals Corporation (INEX; IEX) announced that it has expanded the clinical development program for its lead anticancer product Onco TCS to include a new phase I/II human clinical trial...

Positive results announced in phase II clinical trial of INS37217.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Inspire Pharmaceuticals, Inc., (ISPH) announced that results of a phase II clinical trial for INS37217 Intranasal in patients with perennial allergic rhinitis (PAR). INS37217 demonstrated...

Second quarter and 6-month results announced.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- International Isotopes, Inc., (INIS) announces sales, earnings and earnings per share for the second quarter and 6 months ended June 30, 2002. Sales for the second quarter ended June 30, 2002,...

Jerry Jackson named to board of directors.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- IntraBiotics Pharmaceuticals, Inc., (IBPI), announced that Jerry Jackson has been elected to its board of directors effective August 1. Jackson will replace Jane Shaw, PhD, who has resigned to focus...

Device manufacturer closes on first tranche of a $30M round of financing.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Medical device manufacturer IntraLuminal Therapeutics, Inc., Carlsbad, California, the first company to develop a guided crossing wire system for safely crossing total occlusions (TO), has recently...

Opacification a problem with hydrophilic intraocular lenses.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Opacification of hydrophilic acrylic intraocular lenses can occur months after implantation, requiring additional surgery to replace. Hakan F....

Companies cancel reciprocal financial obligations.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Isis Pharmaceuticals, Inc., (ISIS) and Hybridon (HYBN) announced the cancellation of the remaining financial obligations related to their collaboration and license agreement that the companies completed...

Milestone achieved in drug discovery collaboration.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Isis Pharmaceuticals, Inc., (ISIS) announced that it has achieved a research milestone in its drug discovery collaboration with Amgen (AMGN). Isis has received a payment from Amgen for the...

SBIR award will help to develop neocartilage chondral allograft.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Isto Technologies, Inc., announced that the company has been awarded a $750,000 Small Business Innovation Research grant from the National Institute of Health (NIH), National Institute of Arthritis and...

Developer of protein kinase-targeting drugs announces reorganization designed to cut costs.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Keryx Biopharmaceuticals, Inc., (KERX; KRX), a drug discovery company focused on developing innovative therapies through its proprietary technologies for the treatment of critical medical conditions,...

L. Robert Johnston, Jr., named as a director.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- LaunchCyte, the 2-year-old for-profit incubator that creates, seeds, and harvests life science innovations, announced the appointment of L. Robert ("Bob") Johnston, Jr., to its board of directors,...

Novel chemotypes against kinase target identified.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Libraria, Inc., and the Genomics Institute of the Novartis Research Foundation (GNF) announced the discovery of several novel chemotypes that inhibit an important kinase target in a successful...

gag-based DNA vaccine effective in primates.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- by Michael Greer, senior medical writer - An HIV DNA vaccine can produce sustained and effective cell-mediated immune responses to the virus in animals, researchers in the United States report. ...

MFSI receives Army and DARPA contracts for biodefense technology.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- MicroFluidic Systems, Inc., (MFSI), a privately held company based in Pleasanton, California, has received a contract for over $550,000 dollars from the U.S. Army's Soldier Biological and Chemical...

Company launches SoftMax tools for FDA compliance.
October 2, 2002... 2002 OCT 2 - (NewsRx.com & NewsRx.net) -- Molecular Devices Corp. (MDCC) has announced the launch of SoftMax Pro Enterprise software. This new software provides tools necessary for Food and Drug Administration (FDA) 21 CFR Part 11...